In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease.
Hosts: Daniel Griffin and Vincent Racaniello
Click arrow to play
Download TWiV 713 (21 MB .mp3, 35 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Novavax vaccine phase 3 results (Novavax) 1:37
- J&J vaccine phase 3 results (J&J) 4:58
- COVID-19 and transmission in K-12 schools (MMWR) 18:38
- Lilly mAb therapy (NEJM) 20:18
- Regeneron mAb prophylaxis (Regeneron) 21:54
- Colchicine for COVID-19 (Cardiol Today) 24:45
- Letters read on TWiV 713 28:32
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Interesting that India came up in a letter.
Maybe ask about this treatment.
Ziverdo
https://www.rxindia.com/medicines/medicines-by-therapeutic-class/covid-19/ziverdo-kit/
Thanks
Doctors in New York State
https://www.google.com/amp/s/buffalonews.com/news/local/unapproved-by-fda-ivermectin-useful-as-covid-19-treatment-local-doctors-say/article_8ee56f1a-625d-11eb-b771-b76fa82cbedb.amp.html